Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice

Combined checkpoint blockade (e.g., PD1/PD-L1) with traditional clinical therapies can be hampered by side effects and low tumour-therapeutic outcome, hindering broad clinical translation. Here we report a combined tumour-therapeutic modality based on integrating nanosonosensitizers-augmented noninvasive sonodynamic therapy (SDT) with checkpoint-blockade immunotherapy. All components of the nanosonosensitizers (HMME/R837@Lip) are clinically approved, wherein liposomes act as carriers to co-encapsulate sonosensitizers (hematoporphyrin monomethyl ether (HMME)) and immune adjuvant (imiquimod (R837)). Using multiple tumour models, we demonstrate that combining nanosonosensitizers-augmented SDT with anti-PD-L1…

• NN
  National Natural Science Foundation of China

  Awards: 2016YFA0203700, 81725008, 81671695, 81501474, 81501473, 51672303, 51722211, 81771836, 81601501, 81601502
• SA
  Science and Technology Commission of Shanghai Municipality

  Awards: 18XD1404300, 14441900900, 16411971100
• PO
  Program of Shanghai Subject Chief Scientist

  Award: 18XD1404300